In this study we have formulated and characterized immunoliposomes direct to PEL cells using the cationic lipid DOTAP and a pegylated cholesterol funzionalized with a maleidoimide moiety capable to stable interact with anti CD 138 antbody. The formulation was characterized in comparison with only pegylated systems and DOTAP liposomes. These liposomes were used to transfect a model of FITC-ODN into the target cells. The efficiency of these carriers was evaluated using flow cytometry and confocal analysis. The results confirm the higher transfection efficiency of the immunoliposomes if compared with conventional and pegylated liposomes.
Immunoliposomes for the delivery of SiRNA and chemioterapeutic agent to primary effusion lymphoma / Belletti, Daniela; Ruozi, Barbara; Riva, Giovanni; Barozzi, Patrizia; Luppi, Mario; Forni, Flavio; Vandelli, Maria Angela. - STAMPA. - -:(2010), pp. ---. (Intervento presentato al convegno Third Biotech Workshop “Drug Delivery Systems for Biotech Products tenutosi a Pavia nel March 24-25).
Immunoliposomes for the delivery of SiRNA and chemioterapeutic agent to primary effusion lymphoma
BELLETTI, Daniela;RUOZI, Barbara;RIVA, Giovanni;BAROZZI, Patrizia;LUPPI, Mario;FORNI, Flavio;VANDELLI, Maria Angela
2010
Abstract
In this study we have formulated and characterized immunoliposomes direct to PEL cells using the cationic lipid DOTAP and a pegylated cholesterol funzionalized with a maleidoimide moiety capable to stable interact with anti CD 138 antbody. The formulation was characterized in comparison with only pegylated systems and DOTAP liposomes. These liposomes were used to transfect a model of FITC-ODN into the target cells. The efficiency of these carriers was evaluated using flow cytometry and confocal analysis. The results confirm the higher transfection efficiency of the immunoliposomes if compared with conventional and pegylated liposomes.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
